IQVIA Holdings Inc. Reports Strong Q2 2026 Performance and Raised Full-Year Guidance
IQVIA Holdings (IQV) reported accelerated organic revenue growth of 6% year-over-year in the second quarter of 2026, driven by improved market conditions and strong operational execution across its segments. The R&D Solutions segment saw increased demand, particularly from Emerging Biopharma clients who now account for 70% of global clinical trial starts. Commercial Solutions benefited from a surge in new drug launches, while the company is capturing significant market share through outsourcing full commercialization services. IQVIA raised its full-year guidance to reflect higher organic revenue growth and increased M&A contribution despite reduced foreign exchange benefits. Management anticipates continued expansion in the CRO industry due to AI-driven advancements in drug discovery and an expected doubling of study portfolios by large pharma clients, requiring significant scaling of IQVIA's workforce. Operational productivity programs contributed 90 basis points of margin expansion, offsetting non-operational headwinds. The company also completed its acquisition of Charles River assets during the quarter.
Tickers: $IQV
Topics: AI in drug discovery clinical trials outsourcing pharmaceuticals